Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron

G C Bell; K E Caudle; M Whirl-Carrillo; R J Gordon; K Hikino; C A Prows; A Gaedigk; Jag Agundez; S Sadhasivam; T E Klein; M Schwab

doi:10.1002/cpt.598

Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron

Clin Pharmacol Ther. 2017 Aug;102(2):213-218. doi: 10.1002/cpt.598. Epub 2017 Apr 6.

Authors

G C Bell¹, K E Caudle², M Whirl-Carrillo³, R J Gordon⁴, K Hikino⁵, C A Prows⁶, A Gaedigk⁷, Jag Agundez^{8

9}, S Sadhasivam^{10

11}, T E Klein³, M Schwab^{12

13

14}

Affiliations

¹ Personalized Medicine Program, Mission Health, Asheville, North Carolina, USA.
² Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
³ Department of Genetics, Stanford University, Stanford, California, USA.
⁴ University of California, San Diego, Department of Anesthesiology, San Diego, California, USA.
⁵ Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois, USA.
⁶ Division of Human Genetics, Division of Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
⁷ Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy-Kansas City, Kansas City, Missouri, USA.
⁸ Department of Pediatrics, University of Missouri-Kansas City, Kansas City, Missouri, USA.
⁹ Department of Pharmacology, University of Extremadura, Cáceres, Spain.
¹⁰ Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
¹¹ Department of Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
¹² Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany, and University of Tübingen, Germany.
¹³ Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany.
¹⁴ Department of Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany.

PMID: 28002639
PMCID: PMC5479760
DOI: 10.1002/cpt.598

Abstract

5-hydroxytryptamine type 3 (5-HT₃) receptor antagonists are used in the prevention of chemotherapy- induced, radiation-induced and postoperative nausea and vomiting. CYP2D6 polymorphisms can influence the metabolism of some of these drugs (i.e. ondansetron and tropisetron) thereby affecting drug efficacy. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for ondansetron and tropisetron based on CYP2D6 genotype (updates at www.pharmgkb.org).

Publication types

Practice Guideline
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antiemetics / pharmacology
Cytochrome P-450 CYP2D6 / genetics*
Drug-Related Side Effects and Adverse Reactions / prevention & control*
Genetic Testing / methods*
Humans
Ondansetron / pharmacology*
Pharmacogenetics / methods
Polymorphism, Genetic
Postoperative Nausea and Vomiting / prevention & control*
Radiotherapy / adverse effects
Serotonin 5-HT3 Receptor Agonists / pharmacology
Tropisetron / pharmacology*

Substances

Antiemetics
Serotonin 5-HT3 Receptor Agonists
Ondansetron
Tropisetron
Cytochrome P-450 CYP2D6

Abstract

Publication types

MeSH terms

Substances

Grants and funding